SAM
KITE

Solaris Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Solaris Asset Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-825
Closed -$37K – 293
2016
Q4 		$37K Buy
+825
New +$40.5K 0.02% 184

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Solaris Asset Management's KITE Position: Q1 2017 in Review

Solaris Asset Management sold out of Kite Pharma, Inc. (KITE) in Q1 2017, closing a stake of 825 shares — an estimated $37K sold.

Solaris Asset Management first reported a position in KITE in Q4 2016 and held it in 1 quarter. The position peaked at $37K in Q4 2016. 209 funds tracked by Wall St. Rank hold KITE as of Q1 2017.

  • Solaris Asset Management reported no remaining Kite Pharma, Inc. position as of Q1 2017 after selling out during the quarter.
  • Solaris Asset Management sold 825 Kite Pharma, Inc. shares in Q1 2017, an estimated $37K.
  • Solaris Asset Management first reported a position in Kite Pharma, Inc. in Q4 2016 and held it in 1 quarter.
  • Solaris Asset Management's Kite Pharma, Inc. position peaked at $37K in Q4 2016.
  • 209 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2017.

Based on Solaris Asset Management's 13F filing for Q1 2017, filed 3 May 2017.